Grtx.Pk

GRTX.PK maintains a strong liquidity position with a current ratio of 11.0, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to $6.375 million, while its total liabilities are only $645,000, resulting in a debt-to-equity ratio of 0.0. This suggests a conservative capital structure with no long-term debt obligations.

In terms of profitability, GRTX.PK demonstrates robust returns with a return on equity (ROE) of 22.75% and a return on assets (ROA) of 20.71%. These figures exceed typical industry benchmarks for biotechnology firms, indicating efficient use of equity and assets to generate profits.

The company's revenue is not segmented by geographic regions or product lines in the provided data, but its total assets of $7.196 million suggest a relatively concentrated business model. Given the absence of detailed segment data, it is unclear whether the company's exposure is diversified or concentrated in specific therapeutic areas or markets.

Looking at the growth trajectory, GRTX.PK has reported a net income of $149.05 million and a free cash flow of $149.05 million. These figures indicate a strong financial performance, although the operating cash flow is negative at -$6.049 million, which may be due to high capital expenditures or other operational costs. The company's outlook for the current fiscal year is positive, with a strong net income and free cash flow.

The risk assessment for GRTX.PK indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's dilution potential is also low, and there are no significant adjustments applied to its valuations. This suggests a stable capital structure with minimal near-term dilution pressures.

Recent events and filings do not show any significant changes or risks for GRTX.PK. The company's financial health appears to be stable, with no major regulatory or operational issues reported in the latest filings.